Evidence map›Paper›PMID 33616876›Full record

ReviewInternal and emergency medicine2021

Unmet needs in the management of exacerbations of chronic obstructive pulmonary disease.

Kiki Waeijen-Smit, Sarah Houben-Wilke, Antonio DiGiandomenico, Ulf Gehrmann, Frits M E Franssen

Open access · hybridAbstract readReview
In one paragraph

Review in Internal and emergency medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. International journal of chronic obstructive pulmonary disease · 2026
    Article
  4. Observational
  5. Article
  6. Exacerbations of COPD.Respiratory care · 2023
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Kiki Waeijen-SmitDepartment of Research and Education, Ciro, Horn, NM, 6085, The Netherlands. kikismit@ciro-horn.nl.ORCID http://orcid.org/0000-0002-3737-7026
Sarah Houben-WilkeDepartment of Research and Education, Ciro, Horn, NM, 6085, The Netherlands.
Antonio DiGiandomenicoDiscovery Microbiome, Microbial Sciences, Biopharmaceuticals R&D, AstraZeneca, Gaithersburg, USA.
Ulf GehrmannTranslational Science and Experimental Medicine, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
Frits M E FranssenDepartment of Research and Education, Ciro, Horn, NM, 6085, The Netherlands.
Maastricht University Medical Centre · NLAstraZeneca (Sweden) · SEAstraZeneca (United States) · USCiro · NL

Funding

AstraZeneca LSHI19003Dutch Top Sector Life Sciences and Health Topconsortia for Knowledge and Innovation LSHI19003
6 · The paper itself

Abstract

Exacerbations of chronic obstructive pulmonary disease (COPD) are episodes of acute worsening of respiratory symptoms that require additional therapy. These events play a pivotal role in the natural course of the disease and are associated with a progressive decline in lung function, reduced health status, a low physical activity level, tremendous health care costs, and increased mortality. Although most exacerbations have an infectious origin, the underlying mechanisms are heterogeneous and specific predictors of their occurrence in individual patients are currently unknown. Accurate prediction and early diagnosis of exacerbations is essential to develop novel targets for prevention and personalized treatments to reduce the impact of these events. Several potential biomarkers have previously been studied, these however lack specificity, accuracy and do not add value to the available clinical predictors. At present, microbial composition and host-microbiome interactions in the lung are increasingly recognized for their role in affecting the susceptibility to exacerbations, and may steer towards a novel direction in the management of COPD exacerbations. This narrative review describes the current challenges and unmet needs in the management of acute exacerbations of COPD. Exacerbation triggers, biological clusters, current treatment strategies, and their limitations, previously studied biomarkers and prediction tools, the lung microbiome and its role in COPD exacerbations as well as future directions are discussed.

Indexed as

Health Services Needs and DemandSymptom Flare UpHumansPulmonary Disease, Chronic ObstructiveBiomarkersChronic obstructive pulmonary diseaseExacerbationsMicrobiomeMicrobiota

Identifiers

PMID33616876
PMCPMC7897880
OpenAlexW3132930888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.